These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Different chemotherapy protocols for intermediate and high grade malignant non-Hodgkin's lymphoma].
    Author: Wang A, Luo Y, Wang Z.
    Journal: Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):215-7. PubMed ID: 10920901.
    Abstract:
    OBJECTIVE: To assess the optinums chemotherapeutic protocols for higher CR rate in the treatment of intermediate and high grade malignant non Hodgin's lyphoma(NHL). METHODS: Seventy-four patients with pathological intermediate and high grade malignant NHL were tried randomly with revised ProMACE-CytaBOM(treatment group) and CHOP(control group). RESULTS: The CR rate was 56.8% in the treatment group and 35.0% in the control group (P > 0.05). In patients with high grade maliganat NHL, the CR rate of ProMACE-CytaBOM was 60.0% as compared with 32.0% of the CHOP (P < 0.05). Patients in both group suffered from similar side effects with tolerable bone marrow supression and gastric irritation. CONCLUSION: ProMACE-CytaBOM is a safe regimen with relative high CR rate for high grade malignant NHL, but further research is indicated for remote results.
    [Abstract] [Full Text] [Related] [New Search]